US FDA accepts AMAG's resubmission of Feraheme for anaemia
This article was originally published in Scrip
The US FDA has accepted AMAG Pharmaceuticals' resubmission of its lead candidate, Feraheme (ferumoxytol injection) – an iron replacement treatment for iron deficiency anaemia in chronic kidney disease – following its complete response letter in December.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.